Latest filing published 03 Feb 2023 for Lumos Pharma, INC., €3,241.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David B. Karpf: trading record in brief
This profile gathers the share dealings of David B. Karpf in Lumos Pharma, Inc., where the filings describe the role as senior executive. In total, 4 filings cover trades dated from 1 February 2022 to 1 February 2023.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 3 February 2023: a share grant of €117, in Lumos Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to David B. Karpf
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,000 shares@ US$3.5227.7% of flowCommon StockSEC:0001126234-23-000014:0
- 570 shares@ US$8.5341.8% of flowCommon StockSEC:0001126234-22-000101:0
- 400 shares@ US$10.0230.5% of flowCommon StockSEC:0001126234-22-000008:0
3 of 3 declarations